Companies · DH
Definitive Healthcare
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Sep 2, 2026
Advent International proposes $1.02/share going-private transaction for Definitive Healthcare
Advent International made a non-binding proposal on September 2, 2026, to acquire Definitive Healthcare for $1.02 per share of Class A common stock, an all-cash offer. The Special Committee of the Board, composed entirely of independent directors, will evaluate the proposal in consultation with financial and legal advisors. The company provided no financial guidance or confirmation that it will pursue the transaction, and cautions there is no assurance any deal will be consummated.
Tone: neutralRevenue
$241.5M
DH 10-K · FY 2025
Employees
686
Revenue FY2024
$252.2M
Founded
2011
Profile
DH 10-K Item 1 · Feb 26, 2026Definitive Healthcare is a SaaS-based provider of healthcare commercial intelligence, delivering data, analytics, and expertise on the U.S. healthcare ecosystem to approximately 2,330 customers. The company serves three primary end markets — Life Sciences, Provider, and Diversified — with subscription-based access to its platform. Its data products help customers with product development, go-to-market planning, and sales and marketing execution.
Read filing description ↓ Collapse description ↑
Definitive Healthcare is a leading provider of healthcare data and analytics. We provide accurate, comprehensive information on healthcare providers and their activities, enabling customers to make informed decisions across product development, go-to-market planning, and sales and marketing execution. We also offer claims and consumer analytics built from modeled data on millions of unique consumers to help healthcare organizations target, message, and engage specific healthcare audiences. Delivered through our SaaS products and solutions, our data is important to the commercial success of our approximately 2,330 customers as of December 31, 2025 and can be applied in ways that ultimately benefit patient access and care. We generally define a customer as a company that maintains one or more active paid subscriptions. We serve three primary end markets: Life Sciences, Provider, and Diversified. Our Life Sciences customers comprise biopharmaceutical and medical device companies. Providers comprise hospitals, health systems, and other care delivery organizations. Diversified customers include healthcare information technology companies and other organizations operating within the healthcare market, such as staffing firms, commercial real estate firms, financial institutions, and marketing and advertising agencies. Within these organizations, our data serves a broad set of functional groups, including sales, marketing, clinical research, product development, strategy, talent acquisition, and physician network management. Customers access our data products on a subscription basis, and we generate substantially all our revenue from subscription fees.
Primary products
- SaaS-based healthcare data products and solutions
- healthcare commercial intelligence platform
- claims and consumer analytics
- intelligence modules
- workflow products
End markets
Geographies
Named competitors
“While we believe no competitor matches our breadth of data and intelligence solutions or offers as comprehensive and accurate a commercial intelligence platform, we compete either directly or indirectly with: Legacy raw claims data providers, such as Clarivate, IQVIA, and Symphony Health; Emerging point solution players, such as AcuityMD and MedScout; Niche healthcare specialists, such as Komodo Health, H1 Healthcare, Trella Health, and Trilliant Health; Ecosystem players that may house or analyze similar intelligence, such as SG2 and Veeva; and Horizontal go-to-market intelligence platforms, such as ZoomInfo, LinkedIn, and Dun & Bradstreet.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Revenue declined from $252.2 million in 2024 to $241.5 million in 2025, driven by elevated customer churn, macroeconomic pressure on Life Sciences customers, and continued disruption from go-to-market restructuring.
The rest of DH is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.